Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 72Lung Neoplasms 34Squamous Cell Carcinoma of Head and Neck 32Head and Neck Neoplasms 30Urinary Bladder Neoplasms 19Uterine Cervical Neoplasms 18Stomach Neoplasms 17Esophageal Neoplasms 17Small Cell Lung Carcinoma 16Cholangiocarcinoma 16Neoplasm Metastasis 13Ovarian Neoplasms 12Carcinoma, Squamous Cell 11Breast Neoplasms 11Neoplasms 10Mesothelioma, Malignant 9Esophageal Squamous Cell Carcinoma 8Biliary Tract Neoplasms 8Sarcoma 7Fallopian Tube Neoplasms 7Pancreatic Neoplasms 6Mesothelioma 6Adenocarcinoma of Lung 6Adenocarcinoma Of Esophagus 6Recurrence 5Gallbladder Neoplasms 5Carcinoma, Ovarian Epithelial 5Bile Duct Neoplasms 5Triple Negative Breast Neoplasms 4Osteosarcoma 4

Interventions

tislelizumab 1Paclitaxel 1Injections 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Extensive Stage Small Cell Lung Cancer × Cisplatin × Clear all
NCT06897579 2026-04-28

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
40 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡